ETV与LAM治疗HBeAg阴性乙型肝炎相关肝衰竭疗效比较  

Comparison of therapeutic effect of ETV and LAM on HBeAg-negative chronic hepatitis B patients complicated with acute liver failure

作　　者：米红 阮跃龙 张立新 刘卫东 张海润 

机构地区：[1]本溪钢铁集团南地医院传染科,辽宁本溪117021

出　　处：《中国热带医学》2015年第3期347-349,共3页China Tropical Medicine

摘　　要：目的比较恩替卡韦和拉米夫定治疗HBe Ag阴性乙型肝炎相关慢加急性肝衰竭患者的临床疗效。方法从2010年12月~2012年12月本溪钢铁集团南地医院收治的HBe Ag阴性乙型肝炎相关慢加急性肝衰竭患者中选取112例为研究对象,随机分成恩替卡韦组和拉米夫定组,每组56例,分别给予恩替卡韦和拉米夫定治疗。对两组患者治疗前和治疗12周后的Hbe Ag滴度、HBV DNA拷贝数、Tbil、整体治疗效果以及不良反应发生情况进行比较和观察。结果治疗前,两组患者各项数据比较差异均无显著统计学意义（P〉0.05）;治疗12周后,恩替卡韦组患者的各项指标水平均明显优于拉米夫定组,且组间数据比较差异均有显著的统计学意义（P均〈0.05）。结论采用恩替卡韦治疗HBe Ag阴性乙型肝炎相关慢加急性肝衰竭的短期临床效果较好,好转率高,肝功能指标改善明显。Objective To compare the therapeutic effect of Entecavir（ETV）and Lamivudine（LAM） on HBe Ag-negative chronic hepatitis B patients complicated with acute liver failure. Methods The 112 HBe Ag- negative chronichepatitis B patients complicated with acute liver failure were selected from December 2010 to December 2012 and randomlydivided into the ETV group and the LAM group, 56 cases in each group. The titers of HBe Ag, HBV, Tbil, the number of DNAcopies, the overall treatment effect and adverse reactions of the two groups before and 12 weeks after treatment were observedand compared. Results Before treatment no statistically significant differences were noticed in comparisons of everyindictors in the two groups（P 〉0.05）; therapeutic effect of ETV group was superior than that of the LAM group, exhibitingsignificant differences in comparison of all indicators（P 〈 0.05）.Conclusion ETV is efficacy in treatment of HBe Ag-negativechronic hepatitis B patients complicated with acute liver failure with low death rate, high conversion rate and apparentimprovement of liver function.

关 键 词：恩替卡韦 拉米夫定 乙型肝炎 肝衰竭 

分 类 号：R378.21[医药卫生—病原生物学]